Roche’s COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets

  • The serology test has a specificity greater than 99.8% and sensitivity of 100% (14 Days post-PCR confirmation)

  • The high specificity of the test is crucial to determine reliably if a person has been exposed to the virus and if the patient has developed antibodies

  • Roche will provide high double-digit millions of tests already in May for countries accepting the CE mark and in the U.S. under Emergency Use Authorization, further ramping up capacities thereafter

  • The test is available on Roche’s cobas e analysers which are widely available around the world



Original News